









Markets
/
Stocks
/
nasdaq-pasg
/

Passage Bio Inc

PASG

7.170USD

-0.380-5.03%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

1.14MMarket Cap

LossP/E TTM



Passage Bio Inc

7.170

-0.380-5.03%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

228 / 506

Overall Ranking

366 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

64.250

Target Price

+750.99%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.

Overvalued

The company’s latest PE is -0.05, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.78M shares, decreasing 24.29% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 102.03K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.92.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.05, which is 722.45% below the recent high of -0.40 and -1026.20% above the recent low of -0.54.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 228/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.80, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Passage Bio Inc is 63.50, with a high of 120.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.80

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

64.250

Target Price

+796.09%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Passage Bio Inc

PASG

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.45, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 7.96 and the support level at 6.89, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.45

Change

-1.98

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.138

Neutral

RSI(14)

55.169

Neutral

STOCH(KDJ)(9,3,3)

55.016

Neutral

ATR(14)

0.478

High Vlolatility

CCI(14)

120.838

Buy

Williams %R

48.000

Neutral

TRIX(12,20)

0.394

Sell

StochRSI(14)

4.845

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

7.194

Sell

MA10

7.092

Buy

MA20

7.123

Buy

MA50

6.497

Buy

MA100

3.437

Buy

MA200

1.990

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 57.30%, representing a quarter-over-quarter decrease of 3.97%. The largest institutional shareholder is The Vanguard, holding a total of 102.03K shares, representing 3.21% of shares outstanding, with 3.84% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Lynx1 Capital Advisors LLC

9.26M

Vestal Point Capital, LP

6.10M

OrbiMed Advisors, LLC

5.91M

-8.99%

New Leaf Venture Partners LLC

2.50M

Erste Asset Management GmbH

2.46M

The Vanguard Group, Inc.

Star Investors

2.07M

Tang Capital Management, LLC

1.50M

Renaissance Technologies LLC

Star Investors

1.41M

+2.08%

Acadian Asset Management LLC

933.76K

-0.97%

BlackRock Institutional Trust Company, N.A.

657.55K

-0.36%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.05, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.79. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.